Blog Posts

Wistar researchers have contributed an important study in the field of HIV eradication, identified novel therapeutic strategies for NRAS mutant melanoma, and characterized the contribution of soluble antibodies produced by B cells in orchestrating immunosuppression in cancer.

The Helen Dean King award is named after Dr. Helen Dean King – a well-respected geneticist and member of Wistar's research staff from 1908 to 1950 who was instrumental in breeding the first standardized laboratory model known as the Wistar rat, which is still used worldwide today.

Wistar's newest Leadership Council member Keith Lampman-Perlman is focused on making new connections for Wistar that will become part of a cross-disciplinary network of support dedicated to cutting edge research.

In the past month, Wistar researchers have discovered a novel mechanism through which mutant p53 enhances metastasis by controlling tumor metabolism and a missing step in one of the mechanisms of cellular response to stress important in B cells. In addition, the Weiner Lab was shortlisted for the Best Research Team category of the annual Vaccine Industry Excellence Awards.

Since preventive vaccines cannot fight the virus in people who have already contracted it, therapeutic vaccines are being developed, and initial results have shown disease regression.